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Background: There is increasing epidemiological evidence of etiological links between general surgery and
sporadic Creutzfeldt-Jakob disease (sCJD) with long incubation periods. The purpose of this study was to identify
specific surgical procedures potentially associated with sCJD to be targeted for preventive presurgical-intervention
guidance.
Results: We propose a three-step clinical guidance outline where surgical procedures associated with sCJD clinical
onset – potentially more contaminant - are taken into account. Data on hospital discharges and surgical procedures
were obtained from Danish and Swedish national in-patient hospital registries for 167 sCJD cases, onset 1987–2003,
and for 835 matched and 2,224 unmatched population controls. Surgery was allocated to different life-time periods
as previously reported, and frequencies were compared using logistic regression analysis. In the year preceding
clinical onset, persons with sCJD underwent a statistically significant higher number of minor surgical interventions
(OR (95% CI): 17.50 (3.64-84.24)), transluminal endoscopies (OR: 2.73 (1.01–7.37)) and gastrointestinal operations
(OR: 3.51 (1.21–10.19)) compared to matched controls. Surgical discharges clustered towards clinical onset. These
differences increased during the clinical period, with statistically significant higher frequencies for both endoscopies
and minor surgery (OR: 13.91 (5.87-32.95), and for main surgical procedures (OR: 2.10 (1.00-4.39)), particularly
gastrointestinal surgery (OR: 6.00 (1.83-19.66)), and surgery contacting skeletal muscle. Comparisons with
unmatched controls yielded similar results for neurosurgery in the clinical period (OR: 19.40 (2.22-168.34)).
Conclusions: These results suggest that some types of surgical procedures are associated with sCJD, after clinical
onset or particularly just before onset. Selective planning of such surgery to minimize instrument/device
contamination or quarantining might be feasible. Conditional to progress in sCJD etiological research, results are
relevant for guidance development.
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Creutzfeldt-Jakob disease (CJD) is a neurodegenerative
disease associated with deposition in brain tissue of a
pathological isoform (termed PrPSc) of the normal cellular
prion protein (PrPC). CJD exists in three forms, namely:
sporadic (sCJD), of unknown etiology; acquired, whether
variant (vCJD) or iatrogenic (iCJD); and caused by muta-
tions in the gene encoding PrP [1]. Surgical transmission
of CJD by tainted instruments has been experimentally
demonstrated [2], and exposure to neurosurgical instru-
ments recently used on a patient with CJD or incubating
the disease constitutes a diagnostic criterion of iCJD in sur-
veillance (http://www.cjd.ed.ac.uk/diagnosis.html). vCJD
has been linked to both dietary exposure to bovine spongi-
form encephalopathy (BSE) and transfusion of blood from
infected donors [3-5], but not to general or dental surgery
[4,6]. The biological plausibility of vCJD transmission by
surgery, and by neurosurgery in particular, is still being
considered [7]. Insofar as sCJD is concerned, there is
increasing, yet limited, epidemiological evidence of signifi-
cant etiological links to: general surgery [8,9] with long
incubation periods [9]; surgery of retina and peripheral
nerves after shorter incubation intervals [10]; and recently -
with conflicting results – to blood transfusion (BT)
connected to surgery after a >10-year lag [11,12].
State-of-the-art guidelines in EU member states
Recommendations for prevention of CJD transmission in
medical settings may correspond either to public health
guidelines (e.g., for blood donor deferral or instrument de-
contamination procedures), or to clinical guidelines (more
oriented towards supporting decision-making by clinicians
and surgeons). A recent report shows that a majority of
EU Member States had official guidelines that included
specific preventive measures covering situations where
symptomatic and asymptomatic CJD patients or persons
at potentially higher risk of CJD had to undergo surgery
[13]. These included written advice for single-use equip-
ment, destruction of contaminated equipment, decontam-
ination of reusable instruments, use of protective clothing,
storing and quarantining surgical instruments, as well as
organizational recommendations. This report suggests
that, should the new risk factors for sCJD be confirmed
[8-11], further guidance will be needed [13].
Rationale for guideline development
Within a background of guidance development for a po-
tential prevention of CJD transmission by surgical instru-
ments, this study would correspond to the first of six
steps differentiated at a recent report on evidence-based
public health advice for communicable diseases, i.e. the
Preparatory, 0 Stage [14]. At such step, in addition to care-
ful descriptive epidemiology of cases (CJD surveillance),
data on incidents are collected. The present study focuseson potential incidents where instrument contamination
may occur, using a case–control design. In consequence,
we outline here a rationale to motivate the application of
the case–control results at time of Developing Advice,
Stage 3.
It must be stressed that considerable progress is yet
needed in assessing evidence of etiological risk of sCJD
from surgery or BT. An ad-hoc group, commissioned by
the European Centre for Disease Prevention and Control
(ECDC), cautiously concluded, after a formal review
aimed to facilitate grading of scientific evidence in re-
ports, that “the strongest evidence of positive associa-
tions for surgical procedures (SPs) and BT, were based
on latency analysis at >10- or >20-year lag” and that “the
positive findings in relation to SP and BT may indicate a
true risk for sCJD, although there may be confounding
of SPs by BT” [15]. The rationale proposed here should
by no means be taken as a guide for advice before all
formal steps of guidance development are followed. At
such time, as suggested by the ECDC Chief Scientist
“methods of classical epidemiology can be merged with
the methodologies developed in evidence-based medicine
to generate an evidence-based methodology for prevention
and control of infectious disease” [14]. We believe that in
the case of CJD such combined approaches – as shown in
this study - can advantageously be early undertaken.
Required epidemiologic data for SP assessment
Traditionally, assessment of CJD transmission risk levels
for specific neurosurgical and ophthalmological proce-
dures has been based on case reports and experimental
data rather than on epidemiological associations. Pro-
posed preventive measures in some EU Member States
have addressed surgery to be undergone by patients with
CJD early in the clinical period or being “at risk of sCJD
or vCJD”, for SPs traditionally rated as high-risk, i.e.,
neurosurgical, ophthalmological and, in the specific case
of vCJD, dental treatment, use of endodontic reamers,
endoscopes in contact with nasal cavity, and maxillo-
facial surgery [13]. Attempts have been made to identify
types of high-risk surgery that are more frequently
performed at advanced incubation or after clinical onset
of CJD, when tainted instrument infectivity can be
higher. For instance, when compared to surgery on
controls, statistically significant excess frequencies have
been reported for coronary surgery in Denmark and
Sweden, and for unspecified surgery at ≤6 years from
onset in Germany [9,16]. In Japan, 4.5% of 760 sCJD
patients underwent surgery before diagnosis and during
the early clinical period; these procedures were neuro-
logical and ophthalmological in 0.8% and 1.8% of such
patients, respectively [17]. It would seem that in the UK,
ophthalmological surgery was performed at a higher
than expected frequency during the early clinical period
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the early clinical period in sCJD, but controlled studies
are scarce.Study purpose
This study sought to outline principles which would be
potentially useful for drawing up guidelines to prevent
sCJD transmission, and describe surgical late-in-life ex-
perience of sCJD that would enable identification of the
characteristics of SPs to which recommendations could
be best applied. Further detailed description of the ra-
tionale lies outside the scope of this study.Results
Outline of guidance
Algorithms used for planning any type of surgery having
the potential to contaminate instruments incorporate the
following two main variables: 1) patient-related infectious
risk level (based on personal assessment, e.g., patients with
PRNP mutations or family history of CJD, or cases where
diagnosis of sCJD has been considered due to clinical
symptoms), and, 2) the putative contaminating power of
the planned procedure (extrapolated from the infectivity
level assigned to tissues to be contacted by reusable in-
struments) [13,19]. In general, high-risk SPs encompass
ophthalmological and neurosurgical procedures. Any po-
tential change in SP assignment to SP risk-level categories
would require theoretical and empirical motivation.Safety or 1/infectiveness 
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Figure 1 Basic components of a potential CJD transmission/inductionThe rationale for prevention outlined in Figures 1, 2 and
3 and Table 1 combines the abovementioned patient- and
SP-related two variables, by adding a patient-SP inter-
action factor. This factor seeks to identify a clinical si-
tuation, in which the intervention indicated corresponds
to a category of SP more frequently conducted on CJD
patients during the latter part of the incubation period or
early clinical stage, at a time when the potential infectivity
of reusable surgical instruments ought to be highest.
There is considerable experimental evidence to support
such high infectivity, e.g., inoculum infectivity increased
with the progression of the infecting animal’s incubation
period in experimental transmission of BSE and scrapie
[20-23]. However, the association between specific SPs
and CJD onset has not been clearly epidemiologically
quantified epidemiologically. The effectiveness of any
guidance in terms of accurately identifying and appro-
priately managing such patient-SP events would first de-
pend on the use of suitable pattern-recognition criteria
for high-risk events, defined in theory by: a) a combin-
ation of patient clinical characteristics; b) the indication
of a SP classifed within a SP group for which an excess
risk of CJD has been reported; for instance, surgery of
Digestive system and spleen [9] or Nose/throat surgery
[8]; and c) any SP identified from among those more
frequently performed during late incubation or early
clinical periods of CJD. Such ad-hoc SP tables and epi-
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Figure 2 Probabilities of occurrence of different potential events associated with CJD transmission.
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http://www.ete-online.com/content/10/1/5The impact of decision-making, using 3-factor al-
gorithms based on the theory proposed in Figures 1, 2
and 3 and Table 1 should be estimated at a later stage of
guidance development from empirical observations. This
impact might be highest if applied to frequent SPs, i.e.,
Lower-risk SPs in STEP II, indicated for frequent clinical
situations denoted in Figures 1–2 as A6 (patients with
neurological signs, CJD not excluded); i.e. corresponding
to P(A6∩B2) and P(A6∩B3) patient-SP events or alterna-
tively to less frequent P(A3∩B2) surgical events involving
patients with family history of CJD and SP associated
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Figure 3 Outline rationale behind an algorithm for estimating infectiv
reusable instruments in a specific clinical situation, as defined by pat
theoretical development of the first two out of three steps. I. Incident
Implementation. Solid arrows indicate time; hollow arrows indicate informabody-system group or rubric, obtained empirically from
hospital statistics and records review and the associations
defined by OR, could subsequently be integrated into rec-
ommendations for managing potentially contaminating
events, particularly in cases where family antecedents or
biological markers of CJD risk were lacking.
Detection of non-random, joint events in which Ai may
represent presence of CJD infectivity
Probabilities in Figure 2, when corresponding to independ-













ity risk potentially associated with tissue remnants adhered to
ient characteristics and planned surgery: Preparatory activity for
/event verification; II. Risk assessment; III. Developing advice/
tion to be considered.
Table 1 Identification of basic information for algorithm building using three aetiological factors, potentially
translated into criteria for action
FACTOR 1. Patient term. Useful in STEPS I, II and III (Figure 3). Probability
-Patient has been clinically diagnosed with sCJD, vCJD, gTSE or iCJD PxP’
-Patient has not been diagnosed with CJD* but is potentially infective due to:
PxP’
a) subclinical CJD* not being excluded;
b) possibility of existence of prodromal symptoms but no CJD* diagnosis suspected;
c) his/her being a symptom-free carrier of a pathologic mutation of PRNP, having a family history of CJD or being “at risk of CJD*” for
public health purposes; or
d) CJD* diagnosis suspected owing to clinical symptoms.
where,
P= daily incidence of indicated SP among patient’s age- and sex- group; and
P’ = prevalence of infective persons among CJD diagnosed, a, b, c or d (A1-7 Figure 3).
FACTOR 2. SP putative risk level as a causal risk factor for a specific CJD form, i.e., vCJD, sCJD or iCJD, as defined by




Categories defined under a new etiological body-system SP classification
Pn= daily incidence of the indicated SP among patient’s age- and sex- group; and,
P’= prevalence of infective persons among patient’s groups (A1-7 Figure 3) undergoing the procedure.
FACTOR 3. Patient/SP interaction term (SP with higher than expected incidence late in CJD course).** To be applied for
situation appraisal, STEP I (Figure 3).
**SPs to be identifed from associations reported by quality studies
For SP categories defined under a body-system SP classification for use as a guide. (P2xP’)xA2
(P3xP’)xA3
An parameter >1 determined by the magnitude of OR>1** for the indicated SP group or rubric, on termination of incubation period
among population converting to CJD* versus population controls.
* Here CJD constitutes a generic term for different forms of acquired Transmissible Spongiform Encephalopathy (TSE).
** Generated in our study from persons who in fact converted to clinical sCJD in Denmark and Sweden in 1987–2003. In future, this will probably be based on
ORs reported in meta-analyses.
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P(B|Α) = P(B) for conditional probability, such that
PðBjΑÞ ¼ P A∩Bð Þ
P Að Þ
Any situation in which P(B) proved to be higher when
CJD was present P(B2|A1) than when it was absent,
P(B2|A7), would be determined by presence of B2 SPs,
namely, P(B2|A1) > P(B2|A7) or P B2jA1ð ÞP B2jA1ð Þ > 1.
Assuming that probabilities could correspond to inci-
dences, joint events characterized by P B2jA1ð ÞP B2jA7ð Þ > 1 excess risk
would be quantified by the odds ratio using logistic models.
As an example, we conduct such an exercise using a
case–control material from Northern Europe.
Study design
Since this was viewed as a cross-sectional observation
study, a reported case–control design was adopted (seerefs. [9,10] for details), including 167 probable or definite
sCJD cases, 78 men and 89 women, residing in Denmark
or Sweden and fulfilling established EuroCJD diagnostic
criteria [24], with clinical onset during the period 1987–
2003. Two sets of randomly chosen population controls
were included, i.e., 835 matched control (MCs, 5:1 by
gender, year, month of birth, and municipality of resi-
dence at death of the corresponding case), and 2,224
unmatched controls (UMCs). Mean and median ages at
clinical onset or ID-2 were 67 and 68 years (range: 40–88)
for cases and MCs, and 60 and 58 years (range: 40–99) for
UMCs. For the purposes of delimiting lifetime intervals
(late-in-life surgical history for cases and standard lifetime
surgical history for controls), two time-windows (TWs)
were defined using two operational dates, namely, date of
death and date of clinical onset for cases, and the corre-
sponding index dates, denoted index dates 1 and 2 (ID-1
and ID-2), for controls [9]. TW-4 covered the 1-year
period preceding operational disease onset or ID-2. TW-5
encompassed the interval between date of operational
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period with the same mean duration, from ID-2 to ID-1,
in controls. Earlier time-windows in life course, TW-1 to
TW-3, not relevant here, were previously studied [9].
Exposure ascertainment
For cases and controls, data on past hospital discharges
[diagnoses, SP codes, and dates of admission and
discharge] were obtained from the National Hospital In-
patient Registers in Sweden and Denmark, and using
discharge dates and personal identifiers, were then
blindly allocated to subjects’ case or control status, one
of the two TWs, and the two pooled TWs. SP codes
were first categorized according to Swedish, Danish, and
Nordic (NOMESCO-NCSP) SP classifications (for de-
tails see ref. [9]). Codes describing procedures that were
not strictly surgical, e.g., delivery, and non-specific
codes, e.g., “investigative procedures connected with
surgery”, were omitted. The overall selected surgical
experience of cases and controls captured by the present
study corresponded to 598 repeated and unrepeated,
and 335 distinct SP codes associated with 364 registered
discharges during TWs 4 and 5.
The abovementioned 598 SPs were subsequently catego-
rized into two major groups [9], namely, “main surgical
procedures” and “subsidiary procedures”. The latter was a
heterogeneous category, which included transluminal
endoscopies, with or without biopsy, and minor invasive
procedures (such as punctures, needle aspiration or
biopsy, and superficial incisions) that, in general, were sys-
tematically included in the SP-classification chapters for
“minor surgical procedures”. A few registered codes corre-
sponding to blood transfusions in Denmark were dropped
from the group of procedures studied. In order to obtain a
picture of potential tissue remnants adhering to surgical
instruments deemed to be reusable, “main surgical proce-
dures” were reclassified by contacted tissue or structure
using a reported method [25,26]. Endoscopies and minor
surgical procedures were not reclassified.
An individual was deemed to be exposed to a specific
type of surgery defined by body-system group or tissue/
structure, during a specific window, when at least one
hospital department discharge associated with at least one
such surgical code under study was found at a date lying
within the designated time interval, with surgical history
in any other window being disregarded.
Data-analysis
We quantified associations between subclinical or clinic-
ally manifested sCJD and specific categories of SP, using
the odds ratio which, for infrequent exposures, approxi-
mately represents the ratio of the proportion of cases
undergoing surgery to that of controls during an identi-
cal, mean, overall life-time interval. Statistical methodspertaining to the design of variables, latency intervals,
multivariate models and procedures for calculation of
95% CIs replicated those used in earlier analyses [9,10].
Exposure, on the other hand, was taken as a binary vari-
able only, i.e., exposed/unexposed.
Ethics
Scientific evaluation and preliminary ethical clearance of
the research proposal was done by the EU Research
Commission’s ”Concerted Action QLRG3-CT-2002-
81223”. The study was formally notified to the Danish
Data Protection Agency (record no. 2003-41-3104) and
approved by the Karolinska Institute Ethics Committee
(South; report no. 452/02, 2002-12-02) and “Regionala
Etiskprövningsnämnden” dnr 04-171T 2004-04-29 1).
Written consent was not given by patients for their in-
formation to be stored in the hospital data base and used
for research since it was not needed. In Sweden, patients
were never personally identified after register linkage
took place by registries administrative officers. A data
base was built after substituting at registries level each
personal identification number by serial individual num-
bers. Data stored in official Swedish registries were used
following legal regulations. The study conforms with
Danish legislation requiring data management after noti-
fication to the Danish Data Protection Agency (Act on
Processing of Personal Data - Act No. 429 of 31 May
2000). According to the Danish legislation, there is no
need for scientific-ethical clearance of registry based
studies, nor is there a need for written consent by cases
(Act nr 593 of 14/06/2011, Section 10 paragraph 2. Add-
itionally all CJD patients had died by the time of data
collection. No biological or tissue data was studied.
Case control study results
The figures for repeated or unrepeated SPs associated
with discharges during separate time-windows were as
follows: 1) 36 for cases, 91 for MCs and 276 for UMCs,
during TW-4; and, 2) 38 for cases, 56 for MCs and 101
for UMCs during TW-5. The distribution of the 598 SPs
by body-system group and case–control status is
depicted in Figure 4, which shows higher frequencies of
minor and digestive system surgery among cases.
Table 2 shows the ORs for main and subsidiary SPs
registered at discharge during TWs 4 and 5, both sepa-
rately and pooled. Compared to MCs, cases in TW-4
registered statistically significant higher frequencies for
subsidiary procedures (ORs (95% CI): 8.06 (3.15–20.63)),
but not for main procedures targeting all body systems
(OR: 1.71 (0.92–3.27)). Findings from comparisons with
UMCs were similar. During TW-5, differences increased,
with cases displaying statistically significant higher fre-
quencies for endoscopies and minor surgery, (OR: 13.91
(5.87–32.95)), as well as for main procedures (OR: 2.10
Figure 4 Percentage distributions of selected SP codes associated with surgical discharges during TWs 4 and 5, classified by
case–control status, body system, and type of subsidiary procedure (n=598). SP categories yielding zero values are not shown.
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almost twice as high as those for UMCs. The overall
pattern of late-in-life invasive or potentially invasive
medical procedures in persons with diagnosed or un-
diagnosed sCJD in TWs 4 and 5, corresponds to an at
least 2-fold frequency of main SPs and a 12-fold fre-
quency of subsidiary examinations.
Patterns of surgical activity undergone by cases and
controls are shown in Table 3 with a breakdown by
body-system group. Compared to MCs, persons with
sCJD in TW-4 underwent: a 20-fold higher frequency of
minor surgical interventions (OR: 17.50 (3.64–84.24)); a
statistically significant 3 to 4-fold higher frequency of
endoscopic examinations and digestive-system surgery,
with similar figures for comparisons with UMCs; and,
in general, a trend-pattern of OR >1 for each SP group
under study. The highest of the statistically non-
significant differences was seen for surgery of heart and
major vessels (OR: 5.75 (0.76–31.7)), when compared to
UMCs. For TW-5, differences between cases and con-
trols increased, with the highest differences being for
minor surgery and neurosurgery (the latter based on two
exposed cases) (OR: 165.1 (44.84–1,070)) and OR: 19.40
(2.03–15.94), respectively), and lower differences for
gastrointestinal surgery (OR: 6.01 (2.03–15.94)), vis-à-vis
UMCs. Based on lower numbers when compared to
MCs, statistically significant, similar differences were
seen for minor and gastrointestinal surgery.
Despite being small, absolute numbers and groups
shown in the columns of Table 3 reveal surgical patterns
for cases and controls. During TW-4, main SP exposures –
i.e., endoscopies and minor surgery excluded - were similar,with two out of three of the most frequent invasive expo-
sures corresponding to surgery on digestive, urinary or
genital organs, 11/14 for cases and 19/26 for MCs. In TW-
5, surgery undergone by cases appeared to differ, in that
two out of three main SP exposures (6+2)/11 corresponded
to surgery of digestive and nervous systems, and minor
surgery, with 18 exposed persons, dominated the scene.
Gastrointestinal surgery accounted for 12/25, i.e., approxi-
mately half of all main SP exposures undergone by cases
during TWs 4 and 5.
The tissue/structure-related pattern of associations is
set out in Table 4. No significant differences with MCs
were observed in TW-4, except for “other tissues”.
Higher frequencies of invasive procedures were seen in
TW-5 for sCJD patients, with differences resulting from
comparisons with UMCs proving statistically significant:
OR 95% CI for SP contacting brain or dura mater (OR:
36.35 (1.86–711.57)) each; and, based on the same con-
trols, skeletal muscle (OR: 2.76 (1.11–6.89)), and peri-
toneum (OR: 5.50 (2.07–14.66)).
Table 5 lists the types of intervention undergone by
sCJD patients for which significant excess risk was
observed in TW-4 or TW-5. Insofar as main SPs were
concerned, cases in TW-4 registered a high number and
a considerable range of gastrointestinal interventions, as
well as gynecological and urological procedures, with
coronary surgery being undergone by the two cases for
whom surgery of heart and major vessels had been
recorded. During the clinical period, in contrast, main
SPs displayed a distinct, more uniform pattern, with per-
cutaneous gastrostomy proving the most frequent inter-
vention and neurosurgical interventions, craniotomy/
Table 2 Associations for main surgical and subsidiary procedures, for specific periods adjacent to clinical onset or ID-2,
separately and combined
Unexposed Exposed* Surgery targeted
by study
Time window Surgery under study Subject No. (%) No. (%) OR (95% CI)
Time window 4 Main surgical Case 153 (91.6) 14 (8.4)
procedures MC 793 (95.0) 42 (5.0) 1.71 (0.92–3.17)
UMC 2,114 (95.1) 110 (4.9) 1.51 (0.80–2.64)
Subsidiary Case 155 (92.8) 12 (7.2)
procedures** MC 826 (98.9) 9 (1.1) 8.06 (3.15–20.63)
UMC 2,193 (98.6) 31 (1.4) 4.78 (2.27–9.49)
Time window 5 Main surgical Case 156 (93.4) 11 (6.6)
procedures MC 807 (96.6) 28 (3.4) 2.10 (1.00–4.39)
UMC 2,175 (97.8) 49 (2.2) 3.14 (1.50–6.08)
Subsidiary Case 147 (88.0) 20 (12.0)
procedures MC 827 (99.0) 8 (1.0) 13.91 (5.87–32.95)
UMC 2,213 (99.5) 11 (0.5) 28.52 (13.09–65.24)
Time windows 4 and 5 combined Main surgical Case 143 (85.6) 24 (14.4)
procedures MC 770 (92.2) 65 (7.8) 1.99 (1.21–3.30)
UMC 2,071 (93.1) 153 (6.9) 2.05 (1.25–3.25)
Subsidiary Case 137 (82.0) 30 (18.0)
procedures MC 819 (98.1) 16 (1.9) 11.77 (6.00–23.06)
UMC 2,184 (98.2) 40 (1.8) 11.94 (6.94–20.45)
M. Matched control; UMC. Unmatched control.
ORs for comparisons with unmatched controls were adjusted for age, sex and country.
* At least one registered procedure.
** Endoscopies or minor surgery.
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patients. SP patterns in TWs 4 and 5 also differed by
contacted tissue/structure, with “other tissues” in TW-4
and “skeletal muscle”, “peritoneum”, “brain” and “dura
mater” in TW-5 being the most representative features.
Patterns were rather similar for subsidiary procedures,
such as transluminal endoscopies exploring the digestive
and urinary systems, and in the case of Sweden alone,
mainly lumbar punctures.
Figure 5 depicts the quarterly distribution of surgical
discharges for main and subsidiary procedures undergone
by cases and MCs in TW-4. Twenty discharges of cases
and 75 discharges of MCs were associated with main SPs,
with heterogeneity tests p=0.033 and p=0.097, respect-
ively. Sixteen discharges associated with subsidiary pro-
cedures were observed for each group, with heterogeneity
significance (χ2 test) being p=0.000 for cases and p=0.788
for MCs. Discharges connected with main and subsidiary
procedures clustered towards onset in cases (n=20 for
main SP, and n=16 for subsidiary procedures) but not
towards ID-2 in MCs (n=75 for main SP and n=16 for
subsidiary procedures) . No clear patterns were seen for
distribution by quartiles in TW-5 (data not shown).Discussion
Clinical guidance together with increasing use of dispos-
able surgical instruments, control of inadvertent migration
of potentially tainted instruments between surgical sets,
and improvement of the processing and decontamination
cycle, are considered to be the most important preventive
measures to minimize potential CJD transmission by inva-
sive medical procedures. This study shows that patients
with sCJD in the clinical stage, TW-5, undergo a consider-
ably high frequency of main SPs, for the most part neuro-
surgical and gastrointestinal, and minor SPs in particular,
mostly in the form of lumbar punctures. It also suggests
that, prior to clinical onset, TW-4, subsidiary procedures
such as lumbar punctures and endoscopies, particularly of
the digestive tract, as well as gastrointestinal surgery and a
miscellaneous group of main SPs, occur at a higher than
expected frequency for individuals who will develop sCJD.
Identification of such potentially higher-risk events,
particularly prior to CJD diagnosis, might well constitute a
priority in clinical settings. Evidence-based guidance
development will require consideration of multiple aspects
of the potential transmission process and impact of pre-
ventive measures.
Table 3 Number of cases and controls, and associations for surgery by body system group at discharge, for specific
periods adjacent to onset or ID-2
Unexposed Exposed* Surgery targeted by study
Time window Body-system group Subject No. (%) No. (%) OR (95% CI)
Time window 4 Eye and adjacent Case 166 (99.4) 1 (0.6)
structures MC 833 (99.8) 2 (0.2) 2.50 (0.23–27.57)
UMC 2,217 (99.7) 7 (0.3) 1.77 (0.09–10.51)
Heart and major Case 165 (98.8) 2 (1.2)
thoracic vessels MC 830 (99.4) 5 (0.6) 2.00 (0.39–10.31)
UMC 2,220 (99.8) 4 (0.2) 5.75 (0.76–31.47)
Digestive system Case 161 (96.4) 6 (3.6)
and spleen MC 824 (98.7) 11 (1.3) 2.73 (1.01–7.37)
UMC 2,191 (98.5) 33 (1.5) 2.22 (0.81–5.12)
Urinary system, Case 164 (98.2) 3 (1.8)
male genital organs MC 831 (99.5) 4 (0.5) 3.75 (0.84–16.76)
and other surgery UMC 2,210 (99.4) 14 (0.6) 1.96 (0.44–6.31)
Female genital Case 87(97.8) 2 (2.2)
organs MC 441 (99.1) 4 (0.9) 2.50 (0.46–13.65)
UMC 1,136 (99.0) 12 (1.0) 1.92 (0.29–7.51)
Transluminal Case 161 (96.4) 6 (3.6)
endoscopies MC 826 (98.9) 9 (1.1) 3.51 (1.21–10.19)
UMC 2,199 (98.9) 25 (1.1) 2.57 (0.93–6.08)
Minor surgical Case 160 (95.8) 7 (4.2)
procedures MC 833 (99.8) 2 (0.2) 17.50 (3.64–84.24)
UMC 2,217 (99.7) 7 (0.3) 16.52 (5.34–51.15)
Time window 5 Nervous system Case 165 (98.8) 2 (1.2)
MC 835 (100.0) 0 (0.0) –
UMC 2,222 (99.9) 2 (0.1) 19.40 (2.22–168.34)
Digestive system Case 161 (96.4) 6 (3.6)
and spleen MC 830 (99.4) 5 (0.6) 6.00 (1.83–19.66)
UMC 2,211 (99.4) 13 (0.6) 6.01 (2.03–15.94)
Musculoskeletal Case 165 (98.8) 2 (1.2)
system MC 826 (98.9) 9 (1.1) 1.12 (0.23–5.33)
UMC 2,205 (99.1) 19 (0.9) 1.21 (0.19–4.32)
Skin Case 166 (99.4) 1 (0.6)
MC 833 (99.8) 2 (0.2) 2.50 (0.23–27.57)
UMC 2,223(100.0) 1 (0.0) 24.31 (0.95–622.5)
Transluminal Case 164 (98.2) 3 (1.8)
endoscopies MC 828 (99.2) 7 (0.8) 2.14 (0.55–8.29)
UMC 2,215 (99.6) 9 (0.4) 3.81 (0.82–13.32)
Minor surgical Case 149 (89.2) 18 (10.8)
procedures MC 834 (99.9) 1 (0.1) 90.0 (12.01–674.2)
UMC 2,222 (99.9) 2 (0.1) 165.1 (44.84–1,070)
M. Matched control; UMC. Unmatched control.
*ORs for comparisons with unmatched controls were adjusted for age, sex and country.
At least one registered procedure.
Only categories with exposed cases are shown.
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Table 4 Associations for surgery by contacted tissue/structure, registered at discharge for specific periods adjacent to
onset or ID-2
Unexposed Exposed* Surgery targeted by study
Time window Tissue/structure group Subject No. (%) No. (%) OR (95% CI)
Time window 4 Lymph nodes Case 165 (98.8) 2 (1.2)
MC 831 (99.5) 4 (0.5) 2.50 (0.46–13.72)
UMC 2,216 (99.6) 8 (0.4) 3.13 (0.72–13.69)
Blood vessels Case 165 (98.8) 2 (1.2)
MC 828 (99.2) 7 (0.8) 1.46 (0.33–6.48)
UMC 2,217 (99.7) 7 (0.3) 3.88 (0.82–18.34)
Anterior ophthalmic Case 166 (99.4) 1 (0.6)
structures MC 833 (99.8) 2 (0.6) 2.50 (0.23–27.77)
UMC 2,217 (99.7) 7 (0.3) 1.77 (0.24–13.29)
Skeletal muscle Case 164 (98.2) 3 (1.8)
MC 813 (97.4) 22 (2.6) 0.68 (0.20–2.29)
UMC 2,169 (97.5) 55 (2.5) 0.57 (0.17–1.89)
Peritoneum Case 162 (97.0) 5 (3.0)
MC 826 (98.9) 9 (1.1) 2.78 (0.93–8.32)
UMC 2,194 (98.7) 30 (1.3) 2.13 (0.80–5.66)
Other tissues Case 161 (96.4) 6 (3.6)
MC 826 (98.9) 9 (1.1) 3.51 (1.24–9.96)
UMC 2,190 (98.5) 34 (1.5) 2.02 (0.83–4.93)
Time window 5 Brain Case 165 (98.8) 2 (1.2)
MC 835 (100.0) 0 (0.0)
UMC 2,223 (100.0) 1 (0.0) 36.35 (1.86–711.57)
Dura mater Case 165 (98.8) 2 (1.2)
MC 835 (100.0) 0 (0.0)
UMC 2,223 (100.0) 1 (0.0) 36.35 (1.86–711.57)
Lymph nodes Case 166 (99.4) 1 (0.6)
MC 831 (99.5) 4 (0.5) 1.25 (0.14–11.26)
UMC 2,218 (99.7) 6 (0.3) 2.07 (0.28–15.05)
Skeletal muscle Case 161 (96.4) 6 (3.6)
MC 825 (98.8) 10 (1.2) 3.13 (1.13–8.65)
UMC 2,196 (98.7) 28 (1.3) 2.76 (1.11–6.89)
Peritoneum Case 161 (96.4) 6 (3.6)
MC 832 (99.6) 3 (0.4) 10.00 (2.49–40.15)
UMC 2,210 (99.4) 14 (0.6) 5.50 (2.07–14.66)
Other tissues Case 166 (99.4) 1 (0.6)
MC 826 (98.9) 9 (1.1) 0.56 (0.07–4.41)
UMC 2,214 (99.6) 10 (0.4) 1.66 (0.19–14.86)
M. Matched control; UMC. Unmatched control.
ORs for comparisons with unmatched controls were adjusted for age, sex and country.
* At least one registered procedure.
Only categories with exposed cases are shown.
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Table 5 Late preclinical and clinical patterns of surgical history for sCJD cases




Codes Rubric Stay duration
in days (*mean)
Time window 4
Digestive system and spleen 1 JGA0 Endoscopic polypectomy in rectum 1
1 JDB10 Percutaneous gastrostomy 12
1 JAB30 Repair of inguinal hernia using
prosthetic material
4
2 5353, JKA21 Laparoscopic cholecystectomy 2*
1 JGB10 Partial proctectomy and end colostomy 86
1 JHA00 Anal or perianal incision 90
Heart and major thoracic vessels 1 FMD10 Replacement of aortic valve using
biological prosthesis
8
1 FNC10 Aorto-coronary venous bypass with single
distal anastomosis
8
1 FXB00 Intraoperative partial cardiopulmonary bypass 8
1 FNG00 Dilatation of coronary artery 1
Transluminal endoscopies 4 UJD02 Gastroscopy 16
2 UJF32 Coloscopy 23
2 UJF42 Flexible sigmoidoscopy 1
2 9006 Cystoscopy 10
Minor surgery 6 TAB00 Lumbar puncture 15
1 TJJ00 Percutaneous needle biopsy of liver 34
1 TPH20 Insertion of central venous catheter
through subclavian or brachiocephalic vein
1
Other tissue 1 KJGA05 Endoscopic polypectomy in rectum 1
1 KKED22 Transurethral resection of prostate 7
1 KLCA13 Curettage of cervix and body of uterus 2
1 KKCD02 Transurethral resection of bladder 4
1 JHA00 Anal or perianal incision 90
1 7280 Curettage of uterus for biopsy or as therapy 2
Time window 5
Nervous system 1 AAA10 Biopsy through craniotomy 2
1 AAF00 Ventriculostomy 2
Digestive system and spleen 4 JDB10 Percutaneous gastrostomy 17*
1 JDB00 gastrostomy 30
1 4644 Excision of sigmoid colon 10
Transluminal endoscopies
2 UJD02 Gastroscopy 18
1 4042 Laparoscopy 10
1 UKC02 Cystoscopy 2
Minor surgery 21 330, TAB00 Lumbar puncture 38
1 TPW10 Implantation of vascular injection port 37
Brain 1 KAAA10 Biopsy via craniotomy 2
1 AAF00 Ventriculostomy 2
Dura mater
1 KAAA10 Biopsy via craniotomy 2
1 AAF00 Ventriculostomy 2
Cruz et al. Emerging Themes in Epidemiology 2013, 10:5 Page 11 of 14
http://www.ete-online.com/content/10/1/5
Table 5 Late preclinical and clinical patterns of surgical history for sCJD cases (Continued)
Peritoneum 4 JDB10 Percutaneous gastrostomy 17
1 JDB00 Gastrostomy 30
1 4644 Excision of sigmoid colon 10
1 4042 Laparoscopy 10
Rubrics of surgical procedures significantly more frequently conducted in cases than in controls during the year preceding clinical onset* and during the period
from onset to death, by body-system or tissue/structure group.
*For TW-4, heart and major vessel surgical procedures in cases are also listed.
Mean duration was calculated regardless of whether or not procedures were performed during the same hospital stay.
Certain surgery not significantly associated with sCJD but present in discharges post-cystoscopy, e.g., percutaneous removal of calculus from kidney or urether, was
not listed here.
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based assessment of surgical histories, randomly chosen
controls and accurate life-time measurement, its limita-
tions include a lack of access to hospital surgical records -
offset in part by the high validity of registered SPs- [27]
and exclusion of out-patient surgery and invasive diag-
nostic procedures. Lack of data on surgical judgement and
neurological diagnostic processes hampers assessment of
surgical indication and hospital preventive measures
taken. However, case-selection and case–control differen-
tial SP registration are unlikely [9]. However, the younger
age of controls might perhaps bias comparisons of surgery
of fertile age when using UMCs.
Lumbar punctures, frequently performed in out patient
care, out and gastrostomy form part of the routine diagno-
sis and care of demented patients in both countries. Their
presence in TW-4 casts serious doubts on the accuracy of
the operational time point of clinical onset of sCJD, indi-
cating that both the onset of clinical manifestations and
the neurological or medical examinations, frequently


























Figure 5 Temporal distribution of hospital discharges associated with
preceding clinical onset in cases or ID-2 in matched controls: (a) disch
for MCS); and (b) for discharges associated with endoscopies or mino
indicated in calendar time order.date of clinical onset adopted after examining only one
or two selected hospital records. As a consequence, our
results may have overestimated differences between cases
and controls in TW-4 and underestimated those in TW-5,
particularly as regards endoscopies, lumbar punctures and
digestive system surgery, which constitute a shared
pattern. In practice, this would mean that surgery under-
gone prior to clinical onset would be reduced to almost
expected levels vis-à-vis rates in controls, and that the ex-
cess medical procedures and identification of high-risk
predictors would be ascribed to the early clinical period.
Laske et al. reported statistically non-significant ORs of
6.97 and 3.39 for surgery up to 0.5 and 1 years prior to
clinical onset [16].
Only one patient in TW-4 and none in TW-5 under-
went ophthalmological surgery, thereby differing from the
higher frequencies suggested by British and Japanese stud-
ies [17,18]. It is difficult to establish whether this negative
finding is due to our study’s comparatively lower statistical
power or to high clinical standards in Denmark and
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are possibly present at clinical onset of CJD. The excess of
gastrointestinal surgery in TW-5 can be presumed to be
mainly related to care, which, in TW-4, might in part be
attributable to sCJD-related complaints that may either
have unveiled other ailments or, alternatively, misled clini-
cians facing a patient who might not have been cognitively
intact before sCJD diagnosis. Interestingly, Laske et al.
deemed surgery and other stressful events to be a trigger
of sCJD clinical onset within six months [16].
The statistically non-significant higher frequency of cor-
onary surgery in TW-4 is a particularly interesting finding,
since the only statistical significant association for specific
body systems observed during the nine years preceding
onset/ID-2 with OR 2.03 and 2.58 as compared to MCs
and UMCs, respectively; and at >1 year before onset/ID-2,
was surgery of heart and major vessels, i.e., coronary sur-
gery [9]. The recalculated figures for TWs 3 and 4, i.e., the
10-year period, using a binary variable for exposure, were
OR 2.27 (1.03–5.02) and 3.30 (1.42–7.00), when compared
to MCs and UMCs, respectively. Our results suggest that
coronary surgery is more frequently conducted within a
several-year period predating sCJD onset, adding further
fuel to the debate on reuse of angioplasty catheters [28,29].
In Denmark and Sweden, digestive tract and peripheral
vessel surgery and interventions pertaining to peritoneum,
skeletal muscle and “other tissues” constituted risk factors
for sCJD, when conducted at considerable lags [9]. Fur-
thermore, the results show that most are also associated
with sCJD after clinical onset. Gastrointestinal and ortho-
pedic SPs undertaken at end of life in persons with sCJD
might generate infective remnants of skeletal muscle,
“other tissues” and abdominal structures adhering to in-
struments, consistent both with the “lower” infectivity
level assigned to such tissue by the WHO tissue infectivity
tables [26] and with results of the abovementioned exper-
imental observations [20-23]. Accordingly, warnings
proposed for neurosurgical procedures in general, and for
ophthalmological SPs in Japan and the UK in particular
[17,18], may also apply to procedures overrepresented late
in life among individuals with sCJD. To recapitulate,
experimental, clinical and epidemiological observations
would support the notion that algorithms designed to as-
sess risk when planning surgical interventions in some EU
Member States should include neurosurgical, ophthalmo-
logical and gastrointestinal procedures among those with
higher infective potential.
The results of this and two earlier studies [9,10] cover all
in-patient registered surgery undergone by persons with
sCJD in Denmark and Sweden, and enable an overall pic-
ture to be formed of the relationship between surgery and
sCJD since the early 1970s, which could well be valid for
populations across the industrial world. Surgery is, in gen-
eral, only directly associated with the disorder, and displaysthe following three, principal, etiologically different
patterns: 1) surgery potentially causing sCJD, mainly
conducted 20 or more years before disease onset; 2) surgery
potentially or definitely caused by sCJD, mainly conducted
at some point, early or otherwise, during the clinical course
of the disease; and, 3) coronary surgery conducted in the
10 years preceding onset, which we contend represents a
confounding effect of vascular risk factors acting concur-
rently as a cause of both coronary artheriosclerosis and
sCJD. Subject to confirmation being obtained from inde-
pendent studies, all three types of associations raise points
relevant for designing specific guidelines for the prevention
of sCJD transmission in medical settings.
In surgical practice, national and local traditions vary.
Our results may not necessarily mimic the findings of
prior studies nor be replicated in studies pertaining to
other countries or time intervals. Clinical guidance for
prevention of CJD transmission in medical settings calls
for the study of recent surgical practice in countries where
application of the relevant recommendations is envisaged,
as well as analysis of temporarily overlooked yet relevant
patient-SP specific events, denoted as incidents a
posteriori. Despite a non-neurosurgical incident implicat-
ing consecutive use of same instrument by two persons di-
agnosed with sCJD has never been reported, incident
assessment and management constitutes a distinct, mixed
(clinical and public health) element of guidance for CJD
prevention as current guidelines frequently show [13].
Conclusions
In persons with sCJD certain types of end-of-life surgical
interventions and medical examinations tend to be particu-
larly frequent, e.g., digestive tract endoscopies, abdominal
surgery and, possibly, surgery of nervous system, bone and
coronary vessels. Their nature and indication should be fur-
ther investigated using clinical records, with the aim of
avoiding unnecessary procedures and planning interven-
tions in accordance with evidence-based rules for the pre-
vention of a potential CJD induction in medical settings.
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